Rimonabant Acomplia

 A frequently used teory which consernes obesity treatment is that 95 percent of patiens who lose weight gain it all back.

 A statistic study about this is based on a small study from 1960,but of course is no longer valid. Lots off new things apperes and other have  changed conserning obesity treatment since then. Thousands of people have succeeded in losing weight and keeping it off — an encouraging fact for many that are discouraged by outdated information.

In our days  are several different types of  obesity treatment options to manage weight that are really effective including: dietary therapy, physical activity, behavior therapy, drug therapy, combined therapy and surgery. Weight loss of about 10 percent of body weight has proved to benefit the human  health by reducing many obesity-related risk factors.

Recommendations for treatment are now focusing on 10 percent weight loss to help patients with long-term maintenance of weight loss. Health professionals including physicians, nutritionists, exercise physiologists, psychologists and bariatric surgeons help persons with overweight and obesity to determine the most appropriate treatment.

Drug Therapy as a very important obesity traetment in our days(drugs like Rimonabant Acomplia )

• Drug therapy can be used as a treatment option for persons with: 1) a Body Mass Index (BMI) > 30 with no obesity-related conditions or 2) a BMI of > 27 with two or more obesity-related conditions.
• Drug treatment can be used if the patient is willing to have also an appropriate lifestylein order af a better result.
• Drug therapy may be used for weight loss and weight maintenance.
• People should be regularly assessed to determine the effect and continuing safety of a drug.
• Three weight loss drugs, approved by the US Food and Drug Administration (FDA) for treating obesity, are Orlistat (Xenical), Phentermine, and Sibutramine (Meridia) the the newest and better is Rimonabant Acomplia .

1.       Orlistat works by blocking about 30 percent of dietary fat from being absorbed, and is the most recently approved weight loss drug.

 2.       Phentermine, an appetite suppressant, has been available for many years. It is half of the “fen-phen” combination that remains available for use. The use of phentermine alone has not been associated with the adverse health effects of the fenfluramine-phentermine combination.

 3.       Sibutramine is approved for long-term use, and works to control eating by sending a signal of fullness (satiety) to the brain.

4.       The obesity treatment with Rimonabant  Acomplia is very efficient because it works by blocking the receptors located in the brain that are responsble with the appetite.

Rimonabant Acomplia Helps You Lose Weight

Rimonabant Acomplia is an anorectic anti obesity pill. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is reduction the desire to eat. Obesity is now the most important nutritional desise around the world. Defined as a body mass index of greater than 30, it arises from the accumulation of excess fat in the human body from overconsumption of unhealthy foods. Prevalence of obesity in the US and Europe has reached epidemic levels.

Data from the World Health Organisation show that in some parts of Europe over 70% of men aged 55-65 years are obese or overweight (BMI >25) and almost 70% of women in this age group. One in five of all Americans is obese and one in three overweight. More than that, increasing rates of childhood obesity are likely to exacerbate the trend towards increasing obesity in adulthood.

Rimonabant Acomplia in clinical studies also discovered to be effective in assisting smokers to quit smoking. There is a direct connection true obesity and increased risk of cardiovascular disease and diabetes and possibly certain cancers, such as breast and colorectal cancer. Increases in body weight lead to changes in blood lipid and cholesterol levels, predisposing to increased risk of atherosclerosis.  

Rimonabant Acomplia is called a Miracle Drug .Because Rimonabant helps not only to lose weight as well as to reduce waist size and stop alcoholism also at some extent.

Buy Rimonabant and begin losing weight and quit smoking right away . 

People seeking to buy Rimonabant (Acomplia)can presently do so in one of three possible ways.

1. You can go to a doctor in a country where the sale of Rimonabant has been approved  and if the doctor agrees that you would have some benefits from the Acomplia treatment(which is very very possible), the doctor will write out to you a prescription. You would then go with the prescription to a pharmacy, and buy the diet drug rimonabant.

2. You can contact an online pharmacy in a country(all over the globe) where the sale of Acomplia has been approved . Some of these are already advertising on the internet market. Of course, you will be asked to fill out a brief medical questionnaire for review by a doctor who will then decide whether to issue a prescription.

If you are in the country where the pharmacy is located, Acomplia will be expressed to you and typically will reach you in two or three days.If you reside in a country where the drug is not yet approved (like  the U.S.), the online pharmacy will sent by mail to you the drug Acomplia — typically in an unmarked package — in an effort to prevent its interception by customs. The drug of course will reach you in ten days to a couple of weeks. 

The U.S. Food and Drug Administration takes the position that it is illegal for a foreign pharmacy to ship drugs not approved by the FDA into the United States. Other countries may have similar laws. In practice, very few shipments are intercepted — and some online pharmacies send another package in the rare instances that this occurs.

3. You can contact an online pharmacy in a country where the sale of Acomplia is not yet  approved ( Canada). Some of these also are advertising on the internet market. While the procedure for ordering the diet drug is similar to ordering from a country where Rimonabant Acomplia is legally for sale, we don’t have much information about how third-country pharmacies ( Canadian pharmacies) are filling these orders. 

The European Commission publicly issued a warning to consumers last year– when Sanofi was still not authorized to sell Acomplia anywhere — that fake versions of the diet drug already were being sold over the internet market.“People who buy unlicensed and counterfeit or illicit copies of rimonabant may be putting their health at risk,” the European Commission said.

Because Acomplia is now available is big number of countries you can buy the original diet drug,because is not indicated to buy a fake which can really affect your body.

To buy Rimonabant Acomplia you have 3 option which are now knowen by you,so now the only thing you have to do is to decide of you really want to lose weight.

QUESTIONS AND ANSWERS ON THE SAFETY OF Acomplia (RIMONABANT)
As part of its continuous monitoring of medicines, the European Medicines Agency (EMEA) has
reviewed the available information on the safety of Rimonabant Acomplia (rimonabant), particularly on the
medicine’s psychiatric safety. It has concluded that Rimonabant Acomplia’s benefits continue to outweigh its
risks, but that patients with ongoing major depression or who are receiving antidepressant treatment
should not be prescribed Rimonabant Acomplia and that some of the warnings in the medicine’s prescribing
information should be strengthened.
What is Rimonabant Acomplia?
Rimonabant Acomplia is a medicine containing the active substance rimonabant. It is used together with diet
and exercise to reduce weight in adult patients who are:
• obese (very overweight) with a body mass index (BMI) greater or equal to 30 kg/m
2
, or,
• overweight (BMI greater or equal to 27 kg/m
2
) and also have other risk factors, such as type 2
diabetes or dyslipidaemia (abnormal levels of fat in their blood).
The active substance in Rimonabant Acomplia, is a cannabinoid receptor antagonist. It acts by
blocking a specific type of receptor called cannabinoid type 1 (CB1) receptors. These receptors are
found in the nervous system and are part of the system that the body uses to control food intake. By
blocking the receptors, rimonabant can help patients to reduce food intake and to lose weight. The
receptors are also found in peripheral tissues including adipocytes (fat cells).
Rimonabant Acomplia is authorised in the European Union/European Economic Area, and is marketed in 13
European countries. Rimonabant is also authorised as ZIMULTI, but this product is not marketed in
the European Union.
Why has the EMEA reviewed the medicine?
Rimonabant Acomplia received a positive opinion from the EMEA’s Committee for Medicinal Products for
Human Use (CHMP) on 27 April 2006, and a marketing authorisation from the European Commission
on 19 June 2006. During the approval procedure, the main safety issue identified with the medicine
was psychiatric side effects, especially depression. The company that makes Rimonabant Acomplia was
requested to monitor these side effects.
In June 2007, as part of its continuous monitoring of the safety of this medicine, the CHMP requested
all available information on the psychiatric safety of Rimonabant Acomplia from sanofi-aventis. The review of
this information was finalised at the CHMP meeting of 16-19 July 2007.
Which data has the CHMP reviewed?
The review included information on the psychiatric safety of Rimonabant Acomplia, focusing on cases of
depression in patients taking the medicine, including suicidal ideation (thoughts about committing
suicide) and suicide attempts. This information came both from the company’s monitoring of the use
of the medicine from its launch until 18 June 2007, and from five studies involving 781 patients taking
Rimonabant Acomplia, which have been completed since Rimonabant Acomplia was granted marketing authorisation.
What were the conclusions of the CHMP?
The CHMP concluded that the benefits of Rimonabant Acomplia continue to outweigh its risks, except in
patients with ongoing major depression and/or taking antidepressants.
Page 2
It concluded that the risk of depression is approximately doubled in patients taking Rimonabant Acomplia,
compared to obese or overweight patients not taking the medicine. In a small minority of cases, this
could lead to suicidal ideation or even suicide attempts. This doubling of the risk of depression occurs
in all types of patients; however, this risk may be increased in patients with a past history of
depression. Although this pattern of side effects is similar to what was seen during the approval
procedure of the medicine, the CHMP concluded that this increased risk is of concern, since
Rimonabant Acomplia is now being used in patients with a history of psychiatric events. This could result in
patients with depression being at risk of their disease getting worse.
The CHMP also noted that too many patients are taking Rimonabant Acomplia at the same time as
antidepressants, even though Rimonabant Acomplia is not recommended for use in patients also taking
antidepressants.
Therefore, the CHMP recommended the following changes to the medicine’s prescribing information:
• upgrading to a contraindication the warning on the use of Rimonabant Acomplia in patients with
ongoing major depression or taking antidepressants. This means that Rimonabant Acomplia must no
longer be used in these patients,
• adding a warning that treatment with Rimonabant Acomplia should be stopped if a patient develops
depression,
• including additional information on the psychiatric safety of Rimonabant Acomplia.
The Committee also requested that the company provides a letter to be sent to healthcare providers
explaining the changes in recommendations of use for Rimonabant Acomplia.
What is the advice to patients and prescribers?
• Doctors should only prescribe Rimonabant Acomplia according to the updated prescribing information.
• Patients and their family should be aware of the risk of depression in patients taking Rimonabant Acomplia,
and that patients should not take Rimonabant Acomplia if they are taking an antidepressant.
• Patients who start to experience symptoms of depression while taking Rimonabant Acomplia should consult
their doctor.
• Patients who are taking Rimonabant Acomplia and have questions or concerns should talk to their doctor or
pharmacist.